RxDoctor Payments Data

Elizabeth Claydon, MD

Family Medicine · Grass Valley, CANPI 1992140131

Payments from drug & device makers

$298in general payments, 2019–2025

Across 17 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$107
  • Amgen$73
  • Pfizer$46
  • Novo Nordisk$24
  • Dexcom, Inc.$19
  • Boehringer Ingelheim$17
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$28194%
  • Education$176%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$298 in reported general payments places this provider in the 55th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$808,581
Medicare patients
1,312
Services billed
10,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$365,512
OzempicSemaglutide55$122,990
JardianceEmpagliflozin104$116,708
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$83,157
MounjaroTirzepatide41$69,355
JanuviaSitagliptin Phosphate51$46,732
TradjentaLinagliptin41$43,476
TrulicityDulaglutide28$38,771
XareltoRivaroxaban42$38,423
MyrbetriqMirabegron49$34,726
RybelsusSemaglutide23$29,662
Repatha SureclickEvolocumab33$28,965
FarxigaDapagliflozin Propanediol16$23,508
LinzessLinaclotide25$21,818
EntrestoSacubitril/Valsartan12$15,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$365,512353 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$17$172,045156 claims
Novo NordiskOzempic, Rybelsus$24$152,65278 claims
GSKTrelegy Ellipta, Arnuity Ellipta$107$89,86487 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,533 family medicine providers in California.

Other family medicine in Grass Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →